Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $32,698 | 12 | 64.7% |
| Travel and Lodging | $16,792 | 23 | 33.2% |
| Food and Beverage | $1,014 | 33 | 2.0% |
| Education | $14.15 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $26,936 | 58 | $0 (2023) |
| Celgene Corporation | $9,864 | 6 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $8,469 | 6 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $5,250 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,740 | 1 | AstraZeneca Pharmaceuticals LP ($2,740) |
| 2023 | $1,748 | 15 | E.R. Squibb & Sons, L.L.C. ($1,577) |
| 2022 | $1,058 | 4 | Celgene Corporation ($600.00) |
| 2021 | $5,400 | 1 | AstraZeneca Pharmaceuticals LP ($5,400) |
| 2019 | $16,514 | 7 | Celgene Corporation ($9,264) |
| 2018 | $8,344 | 6 | E.R. Squibb & Sons, L.L.C. ($8,344) |
| 2017 | $14,714 | 37 | E.R. Squibb & Sons, L.L.C. ($14,714) |
All Payment Transactions
71 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/25/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| Category: Oncology | ||||||
| 12/21/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $108.40 | General |
| 12/21/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $108.40 | General |
| 12/10/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 12/09/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $120.16 | General |
| 09/28/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $324.66 | General |
| 09/27/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $324.66 | General |
| 09/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $427.81 | General |
| 09/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $60.00 | General |
| 09/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $51.14 | General |
| 09/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $49.75 | General |
| 09/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $30.00 | General |
| 09/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $28.00 | General |
| 09/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $25.62 | General |
| 09/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $25.00 | General |
| 09/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $14.00 | General |
| 11/16/2022 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $91.73 | General |
| 11/16/2022 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $66.67 | General |
| 05/10/2022 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 05/10/2022 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 03/18/2021 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $5,400.00 | General |
| 12/18/2019 | Celgene Corporation | Inrebic (Drug) | Consulting Fee | Cash or cash equivalent | $7,500.00 | General |
| Category: Myelofibrosis | ||||||
| 11/12/2019 | Celgene Corporation | Inrebic (Drug) | Travel and Lodging | In-kind items and services | $756.06 | General |
| Category: Myelofibrosis | ||||||
| 11/12/2019 | Celgene Corporation | Inrebic (Drug) | Travel and Lodging | In-kind items and services | $514.60 | General |
| Category: Myelofibrosis | ||||||
| 11/12/2019 | Celgene Corporation | Inrebic (Drug) | Travel and Lodging | In-kind items and services | $414.80 | General |
| Category: Myelofibrosis | ||||||
About Dr. Margaret Shipp, MD
Dr. Margaret Shipp, MD is a Hematology & Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1699851154.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Margaret Shipp, MD has received a total of $50,519 in payments from pharmaceutical and medical device companies, with $2,740 received in 2024. These payments were reported across 71 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($32,698).
Practice Information
- Specialty Hematology & Oncology
- Location Boston, MA
- Active Since 10/27/2006
- Last Updated 07/09/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1699851154
Products in Payments
- Inrebic (Drug) $9,264
- EMPLICITI (Biological) $6,920
- Vitrakvi (Drug) $5,250
- OPDIVO (Biological) $4,800
- CALQUENCE (Drug) $2,740
- ELIQUIS (Drug) $2,000
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Boston
Dr. Julio Hajdenberg, Md, MD
Hematology & Oncology — Payments: $1.1M
Dr. Eric Jacobsen, Md, MD
Hematology & Oncology — Payments: $1.1M
Paul Richardson, Md, MD
Hematology & Oncology — Payments: $920,265
Matthew Davids, M.d, M.D
Hematology & Oncology — Payments: $808,362
David Avigan, M.d, M.D
Hematology & Oncology — Payments: $679,225
Anthony Letai, Md, MD
Hematology & Oncology — Payments: $569,795